Abstract
The actions of the structurally related proglucagon-derived peptides (PGDPs)—glucagon, glucagon-like peptide (GLP)-1 and GLP-2—are focused on complementary aspects of energy homeostasis. Glucagon opposes insulin action, regulates hepatic glucose production, and is a primary hormonal defense against hypoglycemia. Conversely, attenuation of glucagon action markedly improves experimental diabetes, hence glucagon antagonists may prove useful for the treatment of type 2 diabetes. GLP-1 controls blood glucose through regulation of glucose-dependent insulin secretion, inhibition of glucagon secretion and gastric emptying, and reduction of food intake. GLP-1-receptor activation also augments insulin biosynthesis, restores β-cell sensitivity to glucose, increases β-cell proliferation, and reduces apoptosis, leading to expansion of the β-cell mass. Administration of GLP-1 is highly effective in reducing blood glucose in subjects with type 2 diabetes but native GLP-1 is rapidly degraded by dipeptidyl peptidase IV. A GLP-1-receptor agonist, exendin 4, has recently been approved for the treatment of type 2 diabetes in the US. Dipeptidyl-peptidase-IV inhibitors, currently in phase III clinical trials, stabilize the postprandial levels of GLP-1 and gastric inhibitory polypeptide and lower blood glucose in diabetic patients via inhibition of glucagon secretion and enhancement of glucose-stimulated insulin secretion. GLP-2 acts proximally to control energy intake by enhancing nutrient absorption and attenuating mucosal injury and is currently in phase III clinical trials for the treatment of short bowel syndrome. Thus the modulation of proglucagon-derived peptides has therapeutic potential for the treatment of diabetes and intestinal disease.
Key Points
-
The structurally related proglucagon-derived peptides are produced in the pancreas, gut and brain, and regulate complementary aspects of energy homeostasis
-
The glucagon-like peptide 1 receptor agonist exenatide has recently been approved for treatment of type 2 diabetes
-
Exenatide (exendin 4) and the amylin agonist pramlintide (another drug used to treat type 2 diabetes) also inhibit glucagon secretion
-
Dipeptidyl peptidase IV cleaves incretin hormones such as glucagon-like peptide 1, and drugs that inhibit this enzyme are in phase III trials for treatment of type 2 diabetes
-
Glucagon-like peptide 2 is currently in phase III clinical trials for treatment of short-bowel syndrome
-
Thus various strategies that modulate proglucagon-derived peptides show therapeutic potential in both diabetes and intestinal disease
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bell GI et al. (1983) Exon duplication and divergence in the human preproglucagon gene. Nature 304: 368–371
Mayo KE et al. (2003) International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev 55: 167–194
Patzelt C and Schiltz E (1984) Conversion of proglucagon in pancreatic alpha cells: the major endproducts are glucagon and a single peptide, the major proglucagon fragment, that contains two glucagon-like sequences. Proc Natl Acad Sci USA 81: 5007–5011
Furuta M et al. (1999) Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2. Proc Natl Acad Sci USA 94: 6646–6651
Unger RH and Orci L (1975) The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1: 14–16
Cryer PE (2004) Diverse causes of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med 350: 2272–2279
Hope KM et al. (2004) Regulation of alpha-cell function by the beta-cell in isolated human and rat islets deprived of glucose: the “switch-off” hypothesis. Diabetes 53: 1488–1495
Gosmanov NR et al. (2005) Role of the decrement in intraislet insulin for the glucagon response to hypoglycemia in humans. Diabetes Care 28: 1124–1131
Gelling RW et al. (2003) Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci USA 100: 1438–1443
Liang Y et al. (2004) Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes 53: 410–417
Sloop KW et al. (2004) Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest 113: 1571–1581
Jiang G and Zhang BB (2003) Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab 284: 671–678
Petersen KF and Sullivan JT (2001) Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 44: 2018–2024
Schmitz O et al. (2004) Amylin agonists: a novel approach in the treatment of diabetes. Diabetes 53 (Suppl 3): S233–S238
Ahren B et al. (2004) Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89: 2078–2084
Zhu X et al. (2002) Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects. Proc Natl Acad Sci USA 99: 10293–10298
Drucker DJ et al. (1996) Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 93: 7911–7916
Goke R et al. (1993) Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-cells. J Biol Chem 268: 19650–19655
Dakin CL et al. (2004) Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145: 2687–2695
Cohen MA et al. (2003) Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 88: 4696–4701
Wynne K et al. (2005) Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 54: 2390–2395
Baggio LL et al. (2004) Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 127: 546–558
Brubaker PL and Anini Y (2003) Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2. Can J Physiol Pharmacol 81: 1005–1012
Orskov C et al. (1993) Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 42: 658–661
Nauck MA et al. (2002) Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 87: 1239–1246
Drucker DJ et al. (1987) Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 84: 3434–3438
Drucker DJ (2003) Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 144: 5145–5148
Xu G et al. (1999) Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48: 2270–2276
Kim JG et al. (2003) Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 52: 751–759
Drucker DJ (2003) Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 17: 161–171
Li Y et al. (2003) Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278: 471–478
Wang Q et al. (2004) Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic (INS-1) beta-cells. Diabetologia 47: 478–487
Farilla L et al. (2003) GLP-1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144: 5149–5158
Buteau J et al. (2004) Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 47: 806–815
Turton MD et al. (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379: 69–72
Flint A et al. (1998) Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101: 515–520
Nauck MA et al. (1997) Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol Endocrinol Metab 273: 981–988
Imeryuz N et al. (1997) Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol Gastrointest Liver Physiol 273: 920–927
Baggio LL et al. (2004) Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo. Diabetes 53 (Suppl 3): S205–S214
Abbott CR et al. (2005) The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 1044: 127–131
Nikolaidis LA et al. (2004) Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110: 955–961
Bose AK et al. (2005) Glucagon-like peptide-1 (GLP-1) can directly protect the heart against ischemia/reperfusion injury. Diabetes 54: 146–151
Nikolaidis LA et al. (2004) Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109: 962–965
Scrocchi LA et al. (1996) Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide receptor gene. Nature Med 2: 1254–1258
Gutniak M et al. (1992) Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326: 1316–1322
Rachman J et al. (1997) Near normalization of diurnal glucose concentrations by continuous administration of glucagon-like peptide 1 (GLP-1) in subjects with NIDDM. Diabetologia 40: 205–211
Dupre J et al. (1995) Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes 44: 626–630
Vilsboll T et al. (2003) The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J Clin Endocrinol Metab 88: 4897–4903
Zander M et al. (2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359: 824–830
Meneilly GS et al. (2003) Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. Diabetes Care 26: 2835–2841
Eng J et al. (1992) Isolation and characterization of exendin 4, an exendin 3 analogue from Heloderma suspectum venom. J Biol Chem 267: 7402–7405
Chen YE and Drucker DJ (1997) Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. J Biol Chem 272: 4108–4115
Buse JB et al. (2004) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27: 2628–2635
DeFronzo RA et al. (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28: 1092–1100
Kendall DM et al. (2005) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28: 1083–1091
Degn K B et al. (2004) Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 53: 2397–2403
Agerso H et al. (2002) The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 45: 195–202
Madsbad S et al. (2004) Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 27: 1335–1342
Baggio LL et al. (2004) A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53: 2492–2500
Mentlein R (1999) Dipeptidyl-peptidase IV (CD26)—role in the inactivation of regulatory peptides. Regul Pept 85: 9–24
Meier JJ and Nauck MA (2004) Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide. Best Pract Res Clin Endocrinol Metab 18: 587–606
Hansotia T et al. (2004) Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP4 inhibitors. Diabetes 53: 1326–1335
Marguet D et al. (2000) Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 97: 6874–6879
Ahren B et al. (2002) Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 25: 869–875
Ahren B et al. (2005) Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 28: 1936–1940
Ahren B et al. (2004) Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27: 2874–2880
Conarello SL et al. (2003) Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci USA 100: 6825–6830
Aytac U and Dang NH (2004) CD26/dipeptidyl peptidase IV: a regulator of immune function and a potential molecular target for therapy. Curr Drug Targets Immune Endocr Metabol Disord 4: 11–18
Drucker DJ et al. (1997) Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol 15: 673–677
Munroe DG et al. (1999) Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci USA 96: 1569–1573
Xiao Q et al. (2000) Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease. Am J Physiol Regul Integr Comp Physiol 278: 1057–1063
Schmidt PT et al. (2003) Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety. Regul Pept 116: 21–25
Shin ED et al. (2005) Mucosal adaptation to enteral nutrients is dependent on the physiologic actions of glucagon-like peptide-2 in mice. Gastroenterology 128: 1340–1353
Boushey RP et al. (1999) Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol Endocrinol Metab 277: 937–947
Burrin DG et al. (2005) Glucagon-like peptide 2 dose-dependently activates intestinal cell survival and proliferation in neonatal piglets. Endocrinology 146: 22–32
Haderslev KV et al. (2002) Short-term administration of glucagon-like peptide-2. Effects on bone mineral density and markers of bone turnover in short-bowel patients with no colon. Scand J Gastroenterol 37: 392–398
Henriksen DB et al. (2003) Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res 18: 2180–2189
Jeppesen PB et al. (2001) Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 120: 806–815
Jeppesen PB et al. (2005) Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 54: 1224–1231
Service GJ et al. (2005) Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 353: 249–254
Patti ME et al. Severe hypoglycemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia, in press
Acknowledgements
DJD is supported by a Canada Research Chair in Regulatory Peptides. Work on the glucagon-like peptides in DJD's laboratory is supported by operating grants from the Canadian Institutes for Health Research, the Juvenile Diabetes Research Foundation, and the Canadian Diabetes Association.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D Drucker is a Consultant to Abbott Labs, Amylin Pharmaceuticals Inc, Bristol Myers Squibb, and Eli Lilly Inc, Glaxosmithkline, Merck & Co, Novartis, PPD, Syrrx, and Triad Pharmaceuticals Inc.
Rights and permissions
About this article
Cite this article
Drucker, D. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat Rev Endocrinol 1, 22–31 (2005). https://doi.org/10.1038/ncpendmet0017
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpendmet0017
This article is cited by
-
Gut hormone co-agonists for the treatment of obesity: from bench to bedside
Nature Metabolism (2023)
-
Mammalian models of diabetes mellitus, with a focus on type 2 diabetes mellitus
Nature Reviews Endocrinology (2023)
-
Expression of glucagon-like peptide 1 receptor in neuropeptide Y neurons of the arcuate nucleus in mice
Brain Structure and Function (2022)
-
Contemporary Updates on the Physiology of Glucagon like Peptide-1 and Its Agonist to Treat Type 2 Diabetes Mellitus
International Journal of Peptide Research and Therapeutics (2020)
-
Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice
Scientific Reports (2019)